Other Sessions

ASRS/ESRS Symposium - Systemic Implications of Anti-VEGF Therapy

Thursday 14 May
12.00 – 13.00

Venue: Apollon

Chairperson: J. Cunha-Vaz PORTUGAL

12.00	J. Cunha-Vaz PORTUGAL Anti-VEGF local treatment in high risk patients
12.12	W. Mieler USA Systemic implications of anti-VEGF therapy
12.24	TBC
12.36	G. Williams USA Enzymatic vitreolysis
12.48	Discussion
13.00	End of session

EVER/ESRS Symposium - Physiopathogenic Mechanisms of Macular Edema

Thursday 14 May
12.00 – 13.00

Venue: Clio/Thalie

Chairperson: C. Pournaras SWITZERLAND

12.00	M. Rehak CZECH REPUBLIC Anoxia-hypoxia mediated intracellular mechanisms
12.10	E. Rungger-Brändler SWITZERLAND Blood retinal barrier changes
12.20	E. Stefánsson ICELAND Physics and physiology of macular edema
12.30	B. Bodaghi FRANCE The role of inflammatory mediators
12.40	C. Pournaras SWITZERLAND Cellular mechanisms of traction related macular edema
12.50	Discussion
13.00	End of session

EUROLAM Symposium - Clinical and Surgical Cases of Unusual Presentation and Complex Resolution

Thursday 14 May
14.00 – 15.30

Venue: Clio/Thalie

Chairperson: B. Corcóstegui SPAIN

Co-ordinators: D.E. Pelayes ARGENTINA; U. Schmidt-Erfurth AUSTRIA

Synopsis
Using intraoperative videos and case presentations, a panel of internationally recognised experts will demonstrate their approach to various types of vitreoretinal diseases. Clinical evolution and diagnosis options will also be analysed, along with a review of the different management options employed by the panelists.

Objective
To familiarise participants with specific treatment recommendations and the management of unusual clinical and surgical vitreo retinal diseases.

14.00	J. Verdager CHILE Bilateral Diffuse Uveal Melanocytic Proliferation associated with renal cell carcinoma (BDUMP)
14.09	F. Bandello ITALY Juxtafoveal choroidal neovascularisation secondary to persistent placoid maculopathy treated with intravitreal bevacizumab
14.18	G. Gabela ECUADOR Intravitreal bevacizumab vs intravitreal triamcinolona diabetic macular edema
14.27	S. Seregard SWEDEN Diffuse type retinoblastoma
14.36	G. Richard GERMANY Long-term results after implantation of an epiretinal electrode array
14.45	T. Wolfensberger SWITZERLAND Case Report
14.54	M. Nahemy BRAZIL Oral and intravitreal voriconazole in the management of chronic fungal endophthalmitis
15.03	B. Aylward UK Weird and wonderful retinal detachments
15.12	A. Gaudric FRANCE Vitreoretinal surgery for VHL disease, video presentation
15.21	Open discussion
15.30	End of session

EURETINA Lecture

Thursday 14 May
16.20 – 16.35 (During the Opening Ceremony)

E. Zrenner GERMANY
Can we overcome the fragmented European research space in ophthalmology?

KREISSIG Lecture

Friday 15 May
11.00 – 12.00

Venue: Apollon

B. Aylward VICE-PRESIDENT, EURETINA
Introduction

KREISSIG LECTURE

H. Lincoff USA
The detachment emanating from retinoschisis

I. Kreissig GERMANY
Presentation of AWARD

EVI.CT.SE Retina Section

Saturday 16 May
11.00 – 12.30

Venue: Gallieni 6

The following themes will be addressed in this session organised by the Retina Section of the EVI.CT.SE clinical trials network:

1. J. Cunha-Vaz PORTUGAL
   Status and activities of the Retina Section of EVI.CT.SE.
   Investigator driven clinical trials. Links with DRCR.net
   
   
2. R. Bernardes PORTUGAL
   Biomarkers of progression of retinal disease
   
   
3. P. Massin FRANCE
   Classification of diabetic macular edema
   

Amsterdam Retina Debate

Friday 15 May
12.00 – 13.00

Venue: Apollon

Chairperson: S. Lesnik-Oberstein THE NETHERLANDS

DEBATE 1:	Small gauge surgery (23 and 25 gauge) is the future FOR: G. Williams USA AGAINST: M. de Smet THE NETHERLANDS
DEBATE 2:	All peripheral retinal lesions need treatment FOR: R. Tadayoni FRANCE AGAINST: P. Sullivan UK

French-Israeli Association of Ophthalmology
AFIV SOFI Open meeting

Friday 15 May
13.50 – 17.00

Venue: Gallieni 6

Chairperson: E. Souied FRANCE

13.50	M. Goldstein ISRAEL, E. Souied FRANCE Welcome
14.00	G. Coscas FRANCE OCT features of AMD
14.20	AMD SESSION Moderators: E. Souied FRANCE, A. Lowenstein ISRAEL
1.	A. Lowenstein ISRAEL PHP
2.	S. Yves Cohen FRANCE One-year results of ranibizumab for exudative AMD in a clinical setting
3.	I. Chowers ISRAEL Clinical study in AMD
4.	G. Soubrane FRANCE Features of drusen using adaptative optics
	Discussion
15.00	Break
15.20	MEDICAL RETINA SESSION Moderators: B. Bodaghi FRANCE, M. Goldstein ISRAEL
1.	J. A. Sahel FRANCE Adaptive optics
2.	R. Zolf ISRAEL RPE RIP after anti-VEGF treatment for myopic CNV
3.	M. Paques FRANCE Toward novel classification of RVO
4.	B. Bodaghi FRANCE Viral retinopathies: Past, present and future
5.	M. Goldstein ISRAEL Fluorescein cases
6.	N. Benhamou ISRAEL Fluorescein cases
16.15	SURGICAL RETINA SESSION Moderators: J.F. Korobelnik FRANCE, R. Siegal ISRAEL
1.	A. Alhalel ISRAEL War-related ocular trauma
2.	R. Tadayoni FRANCE Surgical drugs or instruments? Limits and interactions in vitreoretinal surgery
	H. Desatnik ISRAEL Familial exudative vitreo-retinopathy
3.	R. Siegal ISRAEL Bevacizumab in ROP
4.	J.F. Korobelnik FRANCE Triamcinolone as a dye in vitreoretinal surgery
	Discussion
17.00	M. Goldstein ISRAEL Closure

FAN Club - Fluorescein Cases with Discussion

Saturday 16 May
16.30 – 18.00

Venue: Apollon

Chairperson: V. Chong UK

All registered delegates at the EURETINA Congress are welcome to attend this session.
Those who wish to present should prepare a single case presentation and email an intention
of presenting to victor.chong@eye.ox.ac.uk

It is not necessary to submit the case before the Congress, but speakers should upload their presentation at the Speaker Check-In Room by 12.00 on Saturday 16 May.